Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zapaq Inc.

This article was originally published in Start Up

Executive Summary

The founders of Zapaq Inc. have a straightforward objective: to develop compounds that inhibit aspartic proteases. The goal is hardly surprising, given that one of the company's founders, Jordan Tang, PhD, of the Oklahoma Medical Research Foundation was the first scientist to determine the structure of an aspartic protease and explore its basic mechanisms.

You may also be interested in...



With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio

Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel